Literature DB >> 25289805

Prevalence and disability of comorbid social phobia and obsessive-compulsive disorder in patients with panic disorder and generalized anxiety disorder.

Giulia Camuri1, Lucio Oldani, Bernardo Dell'Osso, Beatrice Benatti, Licia Lietti, Carlotta Palazzo, A Carlo Altamura.   

Abstract

OBJECTIVE: Generalized anxiety disorder (GAD) and panic disorder (PD) are disabling conditions, often comorbid with other anxiety disorders. The present study was aimed to assess prevalence and related disability of comorbid social phobia (SP) and obsessive-compulsive disorder (OCD) in 115 patients with GAD (57) or PD (58).
METHODS: Patients were classified as having threshold, subthreshold, or no comorbidity, and related prevalence rates, as well as disability (Sheehan Disability Scale, SDS), were compared across diagnostic subgroups.
RESULTS: SP and OCD comorbidities were present in 30.4% of the sample, with subthreshold comorbidities present at twice the rate of threshold ones (22.6% vs. 11.3%). Compared with GAD patients, PD patients showed significantly higher subthreshold and threshold comorbidity rates (27.6% and 13.8% vs. 17.5% and 8.8%, respectively). Comorbid PD patients had higher SDS scores than the comorbid and non-comorbid GAD subjects. The presence of threshold SP comorbidity was associated with the highest SDS scores.
CONCLUSIONS: SP and OCD comorbidities were found to be prevalent and disabling among GAD and PD patients, with higher subthreshold than threshold rates, and a negative impact on quality of life. Present findings stress the importance of a dimensional approach to anxiety disorders, the presence of threshold and subthreshold comorbidity being the rule rather than the exception.

Entities:  

Keywords:  Anxiety disorders; disability; generalized anxiety disorder; panic disorder; subthreshold comorbidity; threshold comorbidity

Mesh:

Year:  2014        PMID: 25289805     DOI: 10.3109/13651501.2014.959972

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  3 in total

1.  Cognitive behavioral therapy in pharmacoresistant obsessive-compulsive disorder.

Authors:  Jana Vyskocilova; Jan Prasko; Jiri Sipek
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-14       Impact factor: 2.570

2.  An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder.

Authors:  Anish Shah; Joanne Northcutt
Journal:  Ann Gen Psychiatry       Date:  2018-05-11       Impact factor: 3.455

3.  Physical Activity as a Treatment for Social Anxiety in Clinical and Non-clinical Populations: A Systematic Review and Three Meta-Analyses for Different Study Designs.

Authors:  Maya A Zika; Linda Becker
Journal:  Front Hum Neurosci       Date:  2021-06-11       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.